Crohn's Disease News and Research RSS Feed - Crohn's Disease News and Research

Crohn’s disease is a chronic inflammatory disease of the bowel affecting at least 115,000 people in the UK. The condition usually develops in teenagers and young adults, but can be diagnosed at any age and is equally common in men and women.

The condition can affect any part of the digestive tract between the mouth and the anus, although inflammation in the last section of the small bowel (ileum) or the first part of the large bowel (colon) is most common.

Crohn's disease is a ‘relapsing and remitting’ condition characterized by symptom-free periods followed by episodes of “flare-ups,” during which symptoms such as diarrhoea, abdominal pain, fever and fatigue may become particularly bothersome.

Long term, severe inflammation can damage sections of the digestive system, resulting in additional complications, such as a tear in the wall of the anus (fissure), narrowing of the intestine (stricture) or the formation of an abnormal connection between the bowel and another body part such as the bladder, vagina or skin (fistula). Such problems usually require surgical treatment to correct. Crohn's disease also increases the risk of developing bowel cancer.

The exact cause of Crohn's disease is not clear but experts believe a combination of factors may be at work including genetics, immune responses to certain bacteria or viruses and lifestyle factors such as diet or smoking status.
FDA approves new biosimilar for multiple inflammatory diseases

FDA approves new biosimilar for multiple inflammatory diseases

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. [More]
Groundbreaking research findings could lead to potential new treatments for Crohn’s disease

Groundbreaking research findings could lead to potential new treatments for Crohn’s disease

A Case Western Reserve University School of Medicine-led team of international researchers has for the first time identified a fungus as a key factor in the development of Crohn's disease. [More]
Study suggests interactions between distant DNA regions may impact disease gene levels

Study suggests interactions between distant DNA regions may impact disease gene levels

A person's DNA sequence can provide a lot of information about how genes are turned on and off, but new research out of Case Western Reserve University School of Medicine suggests the 3-D structure DNA forms as it crams into cells may provide an additional layer of gene control. [More]
Researchers discover new strategy to boost effectiveness of anti-cancer immune therapy

Researchers discover new strategy to boost effectiveness of anti-cancer immune therapy

Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to maximize the effectiveness of anti-cancer immune therapy. [More]
Researchers uncover specific sites in the genome linked to high blood pressure

Researchers uncover specific sites in the genome linked to high blood pressure

Three large, collaborating international consortia of researchers, including a team co-led by investigators from Brigham and Women's Hospital, have uncovered new genes and sites in the genome tied to elevated blood pressure, implicating certain biological pathways and pointing toward new therapeutic strategies for treating hypertension. [More]
Patients with noninfectious uveitis can get effective treatment from corticosteroid alternative

Patients with noninfectious uveitis can get effective treatment from corticosteroid alternative

Patients suffering from noninfectious uveitis, a group of diseases that causes eye inflammation, can get effective treatment from a corticosteroid alternative that has previously been approved for treatment of arthritis and Crohn's disease, according to a study led by a Duke Health researcher. [More]
New discovery could potentially lead to treatments for Crohn's disease

New discovery could potentially lead to treatments for Crohn's disease

Scientists at the University of British Columbia have made a discovery that could potentially lead to treatments for a debilitating complication of Crohn's disease. [More]
Research strongly links smoking to bowel condition relapses

Research strongly links smoking to bowel condition relapses

Smoking is strongly linked to relapse of a serious bowel condition, research has confirmed. [More]
Crohn's disease sufferers experience slower cognitive response times, study shows

Crohn's disease sufferers experience slower cognitive response times, study shows

New research published in the UEG Journal1 has found that Crohn's disease sufferers experience slower response times than matched individuals that do not have the disease. [More]
Penn scientists develop combined medical and surgical care plan for managing Crohn's disease

Penn scientists develop combined medical and surgical care plan for managing Crohn's disease

The first published combined medical and surgical care plan for managing septic perianal Crohn's disease, a serious complication that occurs in around 40 percent of Crohn's disease patients, has been developed by researchers at Penn State College of Medicine. [More]
Ginger-derived nanoparticles may be good medicine for inflammatory bowel disease

Ginger-derived nanoparticles may be good medicine for inflammatory bowel disease

A recent study by researchers at the Atlanta Veterans Affairs Medical Center took them to a not-so-likely destination: local farmers markets. They went in search of fresh ginger root. [More]
Drugs designed to target nervous system could control inflammation in the gut, study shows

Drugs designed to target nervous system could control inflammation in the gut, study shows

There's a reason it's called a gut feeling. The brain and the gut are connected by intricate neural networks that signal hunger and satiety, love and fear, even safety and danger. These networks employ myriad chemical signals that include dopamine, a powerful neurotransmitter most famous for its role in reward and addiction. [More]
New technology uses natural nano-scale lipid transport system to deliver drugs straight to bloodstream

New technology uses natural nano-scale lipid transport system to deliver drugs straight to bloodstream

For years scientists and dieticians have argued over the health benefits of dietary fat. Research published this week, however, shows that piggybacking onto natural fat absorption pathways can dramatically enhance the utility of some drugs. [More]
Research paves way for development of new drugs to prevent cancer and Alzheimer's

Research paves way for development of new drugs to prevent cancer and Alzheimer's

A new generation of drugs that prevent cancer and Alzheimer's could be developed, thanks to research from the University of Warwick. [More]
Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

A biopharmaceutical company collaborating with Hawai'i scientists on an Ebola vaccine announced encouraging news about its vaccine today. [More]
Fecal transplants may help treat home and hospital-acquired scourge

Fecal transplants may help treat home and hospital-acquired scourge

Fecal transplants are increasingly being used as the treatment of last resort for certain infections in the human gut and have had remarkable success treating the nursing home and hospital-acquired scourge, Clostridium difficile colitis, an infectious diarrhea that often follows antibiotic treatment. [More]
Research sheds new light on development of chronic inflammatory diseases

Research sheds new light on development of chronic inflammatory diseases

Research from life scientists at The University of Manchester has shone new light on the way cells tune in to different inflammatory signals to understand what is happening in the body. [More]
RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, together with IntelGenx Corp., a Canadian drug delivery company focused on oral drug delivery, today announced the signing of an exclusive license agreement with Grupo JUSTE S.A.Q.F (“Grupo JUSTE”), for the commercialization of RIZAPORT™ in Spain, and a right of first refusal for additional territories. RIZAPORT™ is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. [More]
New study may help develop effective medication for severe pain

New study may help develop effective medication for severe pain

The nerve cells that transmit pain signals in the body are called nociceptors. When activated they release pro-inflammatory neuropeptides. In order to recognise harmful external influences, nociceptors are equipped with a wide range of receptors. [More]
Researcher identifies how Itch protein inhibits colonic inflammation and carcinogenesis

Researcher identifies how Itch protein inhibits colonic inflammation and carcinogenesis

Venuprasad Poojary, PhD, an associate investigator at Baylor Institute for Immunology Research (BIIR), part of Baylor Scott & White Research Institute, reported this week in the journal Nature Immunology the role of a key protein in the regulatory pathway that is involved in limiting colon inflammation and tumor growth. [More]
Advertisement